PMID: 11897987Mar 19, 2002Paper

Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs

The Journal of Allergy and Clinical Immunology
David A StempelJay W Meyer

Abstract

Experimental clinical studies have demonstrated that the addition of salmeterol to inhaled corticosteroids (ICSs) is superior to the addition of montelukast to ICSs. Observational research from real-world clinical practice is needed to confirm these results. The present study was designed to assess, in clinical practice, the comparative impact on health care utilization and cost of 2 dual-controller therapies, ICS + salmeterol and ICS + montelukast. This study involved the use of a 24-month pre/post retrospective design in patients continuously enrolled in any of 14 United HealthCare plans. Outcomes assessed were post-index pharmacy costs, rates of emergency department visits and hospitalizations, numbers of filled prescriptions for short-acting beta-agonists (SABAs), total asthma costs, and total health care costs. Subjects in the ICS + salmeterol group had 35% fewer post-index SABA claims than subjects in the montelukast add-on group (P <or=.05). Subjects using ICS + montelukast were 2.5 times more likely to have an asthma-related hospitalization than subjects using ICS + salmeterol (P <or=.065). Total adjusted asthma costs were 63% higher for the patients receiving ICS + montelukast than for the patients receiving ICS + salm...Continue Reading

Citations

Aug 31, 2006·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Keisaku FujimotoKeishi Kubo
Nov 27, 2008·Current Medical Research and Opinion·Thomas E DeleaDavid A Stempel
Jan 9, 2003·Expert Opinion on Pharmacotherapy·Luis García-MarcosNicolás Cobos Barroso
Apr 2, 2005·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Rajesh BalkrishnanMichael S Schechter
Jul 28, 2006·Current Medical Research and Opinion·Felicia C Allen-RameyKevin B Weiss
Jul 29, 2011·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·May HagiwaraRichard H Stanford
Jul 6, 2007·PharmacoEconomics·Ya-Chen Tina ShihRohit Borker
Dec 1, 2006·International Archives of Allergy and Immunology·Qiaoyi ZhangDavid Price
Apr 16, 2010·The Cochrane Database of Systematic Reviews·Francine M DucharmeToby J Lasserson
Jan 25, 2014·The Cochrane Database of Systematic Reviews·Bhupendrasinh F Chauhan, Francine M Ducharme
Sep 28, 2006·PharmacoEconomics·Manabu Akazawa, David A Stempel
Aug 11, 2006·PharmacoEconomics·Pamela C Heaton
Apr 1, 2006·Current Medical Research and Opinion·Richard D O'ConnorPriti M Jhingran
Jun 29, 2016·Journal of the American Geriatrics Society·Shoroq M AltawalbehJoshua M Thorpe
Nov 4, 2008·Pediatrics·Flory L NkoyChristopher G Maloney

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.